

Table S2. Viability (%) assessment of human peripheral blood mononuclear cells (PBMC).

Viability was measured by MTT assay for isolated PBMC culture, congenitins $\beta 5$ or $\beta 7$, LPS, LPS + $\beta 5$ or $\beta 7$, LPS + t $\beta 5$ or t $\beta 7$ during 24 hours.

Treatments including congenitin $\beta 5$ or $\beta 7$ (normal or truncated forms) were added at 10 μg , and LPS at 1 μg . Data represent mean \pm SD from three independent experiments.

Samples	Viability	
	T2D patients	Healthy subjects
LPS	97.5 \pm 3.5	98.3 \pm 2.0
Conglutin $\beta 5$	102.5 \pm 2.3	100.5 \pm 1.5
Conglutin t $\beta 5$	105.0 \pm 4.4	102.0 \pm 3.3
Conglutin $\beta 7$	99.0 \pm 2.2	98.0 \pm 2.2
Conglutin t $\beta 7$	98.9 \pm 2.5	98.4 \pm 2.0
Conglutin $\beta 5$ + LPS	98.3 \pm 2.1	97.8 \pm 1.8
Conglutin t $\beta 5$ + LPS	97.4 \pm 3.5	99.2 \pm 1.5
Conglutin $\beta 7$ + LPS	96.5 \pm 5.6	101.5 \pm 4.3
Conglutin t $\beta 7$ + LPS	101.3 \pm 2.4	100.7 \pm 1.4